Literature DB >> 15339768

Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy.

Adam J Wolfberg1, Colleen Feltmate, Donald P Goldstein, Ross S Berkowitz, Ellice Lieberman.   

Abstract

OBJECTIVE: Complete hydatidiform molar pregnancies occur in approximately 1 of 1,000 conceptions. After uterine evacuation of the trophoblastic tissue, women are followed up with serial serum human chorionic gonadotropin (hCG) measurements. Patients are considered to have attained remission when their hCG level spontaneously declines to an undetectable level and remains there during a 6-month follow-up period. This standard effectively detects all disease recurrence; however, it is resource intensive, delays child bearing, and is subject to significant noncompliance. Our objective was to determine the risk of disease recurrence after hCG spontaneously declines to undetectable levels.
METHODS: We used a database from the New England Trophoblastic Disease Center to analyze hCG levels in patients with complete molar pregnancies.
RESULTS: Among 1,029 women with complete molar pregnancy and complete data, 15% developed persistent gestational trophoblastic neoplasia. The rate of persistent neoplasm among those whose hCG level fell spontaneously to undetectable levels was 0.2% (2/876, 95% confidence interval 0-0.8%). No women developed persistent gestational trophoblastic neoplasia after their hCG level fell to undetectable levels using an assay with a sensitivity of 5 mIU/mL (n = 82, 95% confidence interval 0-4.5%).
CONCLUSION: Based on our experience with women with complete hydatidiform molar pregnancies whose hCG values spontaneously fell to undetectable levels after molar evacuation, we conclude that the risk of recurrent neoplasm after hCG levels fall to less than 5 mIU/mL approaches zero.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15339768     DOI: 10.1097/01.AOG.0000136099.21216.45

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  6 in total

1.  Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia.

Authors:  Raymond J Osborne; Virginia L Filiaci; Julian C Schink; Robert S Mannel; Kian Behbakht; James S Hoffman; Nick M Spirtos; John K Chan; John A Tidy; David S Miller
Journal:  Obstet Gynecol       Date:  2016-09       Impact factor: 7.661

2.  The evolution of methotrexate as a treatment for ectopic pregnancy and gestational trophoblastic neoplasia: a review.

Authors:  Monika M Skubisz; Stephen Tong
Journal:  ISRN Obstet Gynecol       Date:  2012-02-19

3.  Complete molar pregnancy with transformation to choriocarcinoma of the liver: A case report.

Authors:  Danielle Eagan; Natashia Jeter
Journal:  Case Rep Womens Health       Date:  2016-10-19

4.  External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease.

Authors:  L G Kerkmeijer; C M Thomas; R Harvey; F C Sweep; H Mitchell; L F Massuger; M J Seckl
Journal:  Br J Cancer       Date:  2009-03-24       Impact factor: 7.640

5.  Does Postevacuation β -Human Chorionic Gonadotropin Level Predict the Persistent Gestational Trophoblastic Neoplasia?

Authors:  Azam Sadat Mousavi; Samieh Karimi; Mitra Modarres Gilani; Setareh Akhavan; Elahe Rezayof
Journal:  ISRN Obstet Gynecol       Date:  2014-03-24

6.  Early diagnosis of gestational trophoblastic neoplasia based on trajectory classification with compartment modeling.

Authors:  Claire Burny; Muriel Rabilloud; François Golfier; Jérôme Massardier; Touria Hajri; Anne-Marie Schott; Fabien Subtil
Journal:  BMC Med Res Methodol       Date:  2016-01-05       Impact factor: 4.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.